Colesevelam
- Generic Name
- Colesevelam
- Brand Names
- Cholestagel, Lodalis, Welchol
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 182815-43-6
- Unique Ingredient Identifier
- 1XU104G55N
- Background
Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps ...
- Indication
用于以胆固醇升高为主的高脂血症，当饮食和锻炼不能良好达到效果者，可单独使用或与他汀类合用。
- Associated Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH), Hyperlipidemias, Type 2 Diabetes Mellitus, Primary Hyperlipidemia
- Associated Therapies
- -
Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.
- Conditions
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- St. Boniface Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06197763
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 315
- Registration Number
- NCT05252988
- Locations
- 🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital Costa del Sol, Málaga, Andalucía, Spain
🇪🇸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain
Treatment of Bile Acid Malabsorption With Liraglutide
- Conditions
- Interventions
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Filip Krag Knop
- Target Recruit Count
- 52
- Registration Number
- NCT03955575
- Locations
- 🇩🇰
Gentofte Hospital, Hellerup, Regionh, Denmark
Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
- Conditions
- Interventions
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT03270085
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02952963
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, DK, Denmark
Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02876484
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Randomized Trial Comparing Colesevelam vs. Ezetimibe
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- LMC Diabetes & Endocrinology Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT02682680
- Locations
- 🇨🇦
LMC Barrie, Barrie, Ontario, Canada
🇨🇦LMC Brampton, Brampton, Ontario, Canada
🇨🇦LMC Calgary, Calgary, Alberta, Canada
A Study of Colesevelam in Fecal Incontinence
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 88
- Registration Number
- NCT02628626
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
- Conditions
- Interventions
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 4
- Registration Number
- NCT02619812
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
- Conditions
- Interventions
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 13
- Registration Number
- NCT02111603
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.